Tuberculosis in kidney transplant candidates and recipients  

作　　者：Pallavi Prasad Sourabh Sharma Subashri Mohanasundaram Anupam Agarwal Himanshu Verma 

机构地区：[1]Department of Nephrology,Vardhman Mahavir Medical College and Safdarjung Hospital,New Delhi 110029,Delhi,India [2]Department of Nephrology,Prashanth Hospital,Chennai 600042,Tamil Nādu,India

出　　处：《World Journal of Transplantation》2024年第3期59-69,共11页世界移植杂志

摘　　要：Tuberculosis(TB)is the leading cause of infectious mortality and morbidity in the world,second only to coronavirus disease 2019.Patients with chronic kidney disease and kidney transplant recipients are at a higher risk of developing TB than the general population.Active TB is difficult to diagnose in this population due to close mimics.All transplant candidates should be screened for latent TB infection and given TB prophylaxis.Patients who develop active TB pre-or post-trans-plantation should receive multidrug combination therapy of antitubercular therapy for the recommended duration with optimal dose modification as per glomerular filtration rate.

关 键 词：TUBERCULOSIS Latent Antitubercular therapy Kidney transplantation Donor Interferon-gamma release assays TUBERCULIN RIFAMPICIN ISONIAZID 

分 类 号：R52[医药卫生—内科学] R699.2[医药卫生—临床医学]